SCHEMBL29468680

SCHEMBL29468680

CN1C2CCC1CC(OC(=O)N1Cc3ccccc3NC1=O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.98
LMNA P02545 2/20 0.50
HTR3E A5X5Y0 2/20 0.50
HTR3B O95264 2/20 0.50
HTR3A P46098 2/20 0.50
HTR3D Q70Z44 2/20 0.50
HTR3C Q8WXA8 2/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CHRNA7 P36544 1/20 0.50
CHRM2 P08172 4/20 0.49
CHRM5 P08912 4/20 0.49
CHRM1 P11229 4/20 0.49
CHRM3 P20309 4/20 0.49
CHRM4 P08173 3/20 0.49
BLM P54132 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HTR2C P28335 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL508184 1.00 ALOX15 (0.98) ALOX15LMNAHTR3EHTR3BHTR3A
SCHEMBL29462345 1.00 ALOX15 (0.98) ALOX15LMNAHTR3EHTR3BHTR3A
SCHEMBL508185 1.00 ALOX15 (0.98) ALOX15LMNAHTR3EHTR3BHTR3A
SCHEMBL13845405 0.84 ALOX15 (0.71) ALOX15LMNAHTR3EHTR3BHTR3A
SCHEMBL14498120 0.75 ALOX15 (0.58) ALOX15CHRM1CHRM4
SCHEMBL9602046 0.75 ALOX15 (0.58) ALOX15LMNAHTR3EHTR3BHTR3A
SCHEMBL10913532 0.72 ALOX15 (0.55) ALOX15LMNAHTR3EHTR3BHTR3A
SCHEMBL9202802 0.70 ALOX15 (0.53) ALOX15
SCHEMBL2824864 0.69 BRD4 (0.56) ALOX15MEN1KMT2A
SCHEMBL7652481 0.69 HTR3A (0.75) LMNAHTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11285141-B2 Composition and methods for the treatment of myopia Seinda Pharmaceutical Guangzhou Corporation (CN) 2022-03-29 US claimed
US-12102628-B2 Composition and methods for the treatment of myopia Seinda Pharmaceutical Guangzhou Corporation 2024-10-01 US disclosed
EP-3654964-B1 COMPOSITION COMPRISING ATROPINE AND A MIOTIC AGENT AND ITS USE IN THE TREATMENT OF MYOPIA SEINDA PHARMACEUTICAL GUANGZHOU CORP (CN) 2024-04-24 EP disclosed
US-20230062844-A1 COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA Seinda Pharmaceutical Guangzhou Corporation (CN) 2023-03-02 US disclosed
US-11285141-B2 Composition and methods for the treatment of myopia Seinda Pharmaceutical Guangzhou Corporation (CN) 2022-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12102628-B2 Composition and methods for the treatment of myopia CHRM3, CHRM2, MYOC ALOX15 672/4885LMNA 780/4885HTR3E 769/4885
US-11285141-B2 Composition and methods for the treatment of myopia CHRM3, CHRM2, MYOC ALOX15 672/4885LMNA 780/4885HTR3E 769/4885
US-20230062844-A1 COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA CHRM3, CHRM2, MYOC ALOX15 672/4885LMNA 780/4885HTR3E 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.